{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "1757333",
  "DateCompleted": {
    "Year": "1992",
    "Month": "01",
    "Day": "31"
  },
  "DateRevised": {
    "Year": "2017",
    "Month": "12",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "8750-7587",
      "JournalIssue": {
        "Volume": "71",
        "Issue": "3",
        "PubDate": {
          "Year": "1991",
          "Month": "Sep"
        }
      },
      "Title": "Journal of applied physiology (Bethesda, Md. : 1985)",
      "ISOAbbreviation": "J Appl Physiol (1985)"
    },
    "ArticleTitle": "Calcium channel blockers inhibit endogenous pyrogen fever in rats and rabbits.",
    "Pagination": {
      "StartPage": "951",
      "EndPage": "955",
      "MedlinePgn": "951-5"
    },
    "Abstract": {
      "AbstractText": [
        "We have previously shown that febrile responses in both rats and rabbits are elicited by the intravenous injection of a semipurified endogenous pyrogen (EP) prepared from human monocytes. We are now presenting evidence that these febrile responses are mediated via activation of Ca2+ channels by EP. The febrile responses of male New Zealand White rabbits and Sprague-Dawley rats to a standard dose of EP were determined at their respective thermoneutral ambient temperatures. The animals were then treated with Ca2+ channel blocker verapamil (7.5 mg/kg iv) 30-60 min before the EP challenge. In every case the febrile response to EP was markedly attenuated after verapamil pretreatment, while administration of verapamil by itself had no detectable effect on body temperature. Another Ca2+ channel blocker, nifedipine (5 mg/kg iv), was shown to possess antipyretic activity in rats also. To localize where in the fever pathway these Ca2+ channel blockers were acting, we investigated the effect of verapamil at the same dose on fevers that were produced by microinjection of prostaglandin E (PGE) directly into the brain. These PGE fevers were unaffected by verapamil pretreatment, indicating that the antipyretic action of Ca2+ channel blockers occurs before the formation of PGE in response to EP stimulation. The most likely locus of action is the activation of the enzyme phospholipase A2, which regulates the production of arachidonic acid from cellular phospholipids in the prostanoid cascade."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "John B. Pierce Foundation Laboratory, Yale University School of Medicine, New Haven, Connecticut 06519."
          }
        ],
        "LastName": "Stitt",
        "ForeName": "J T",
        "Initials": "JT"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Shimada",
        "ForeName": "S G",
        "Initials": "SG"
      }
    ],
    "GrantList": [
      {
        "GrantID": "NS-11487",
        "Acronym": "NS",
        "Agency": "NINDS NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, U.S. Gov't, P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Appl Physiol (1985)",
    "NlmUniqueID": "8502536",
    "ISSNLinking": "0161-7567"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Calcium Channel Blockers"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrogens"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "leukocyte endogenous mediator"
    },
    {
      "RegistryNumber": "CJ0O37KU29",
      "NameOfSubstance": "Verapamil"
    },
    {
      "RegistryNumber": "F5TD010360",
      "NameOfSubstance": "Alprostadil"
    },
    {
      "RegistryNumber": "I9ZF7L6G2L",
      "NameOfSubstance": "Nifedipine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology"
      ],
      "DescriptorName": "Alprostadil"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Body Temperature"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Brain"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Calcium Channel Blockers"
    },
    {
      "QualifierName": [
        "chemically induced",
        "prevention & control"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "toxicity"
      ],
      "DescriptorName": "Interleukin-1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Microinjections"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Nifedipine"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "toxicity"
      ],
      "DescriptorName": "Pyrogens"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rabbits"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Inbred Strains"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Species Specificity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Stereotaxic Techniques"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Verapamil"
    }
  ]
}